1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Patient demographics with disease, type, and duration of prior bisphosphonate intake, histology, and location/region of BONJ
Patient Sex Age (yr) Disease Bisphosphonate Duration of Treatment Histology Region
1 F 56 Metastases, breast Ca Zoledronic acid (Zometa) 54 mo ON/OM 23–28
2 F 85 MM Zoledronic acid (Zometa) 48 mo ON/OM 44–46
3 F 64 MM Zoledronic acid (Zometa) 48 mo ON 34–37
4 F 60 Metastases, breast Ca Zoledronic acid (Zometa) 48 mo ON 35–36 and 45
5 F 59 Metastases, mamma Ca Zoledronic acid (Zometa) 36 mo ON 14–17
6 F 53 Osteoporosis Ibandronic acid (Bondronat oral) 12 mo ON 45–47
7 F 86 Osteoporosis Ibandronic acid (Bondronat oral) Not available ON 45–47
8 F 79 Metastases, breast Ca Zoledronic acid (Zometa) 7 mo ON 11–15
9 M 66 MM Zoledronic acid (Zometa) 60 mo ON 14–15
10 F 88 Metastases, breast Ca Zoledronic acid (Zometa) Not available Not operated 17–18
Note:—ON indicates osteonecrosis; OM, osteomyelitis; MM, multiple myeloma; Ca, cancer; Mamma, mammary.